Global Oncology Based In-Vivo CRO Market to Reach $2.2 Billion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

| Source: ReportLinker ReportLinker

New York, May 16, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Oncology Based In-Vivo CRO Industry" - https://www.reportlinker.com/p06032380/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Oncology Based In-Vivo CRO Market to Reach $2.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Oncology Based In-Vivo CRO estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$2.2 Billion by 2030, growing at aCAGR of 8.7% over the period 2022-2030. Solid Tumors, one of the segments analyzed in the report, is projected to record 8.7% CAGR and reach US$1.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Blood Cancer segment is readjusted to a revised 7.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $331.3 Million, While China is Forecast to Grow at 8.2% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$331.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.5 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 6.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Select Competitors (Total 42 Featured)
- Champion Oncology, Inc.
- Charles River Laboratory
- Covance
- Crown Bioscience
- Eurofins Scientific
- EVOTEC
- ICON Plc
- Living Tumor Laboratory
- MI Bioresearch, Inc.
- Taconic Biosciences
- The Jackson Laboratory
- Wuxi AppTec
- Xentech


Read the full report: https://www.reportlinker.com/p06032380/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Oncology Based In-Vivo CRO - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR

Table 2: World Historic Review for Oncology Based In-Vivo CRO
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Oncology Based In-Vivo
CRO by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for Solid
Tumors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR

Table 5: World Historic Review for Solid Tumors by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Solid Tumors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for Blood
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR

Table 8: World Historic Review for Blood Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Blood Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Other Indications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR

Table 11: World Historic Review for Other Indications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 12: World 16-Year Perspective for Other Indications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030

Table 13: World Oncology Based In-Vivo CRO Market Analysis of
Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2023
(E)
Table 14: USA Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 15: USA Historic Review for Oncology Based In-Vivo CRO by
Indication - Solid Tumors, Blood Cancer and Other Indications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR

Table 16: USA 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

CANADA
Table 17: Canada Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 18: Canada Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 19: Canada 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

JAPAN
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 20: Japan Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 21: Japan Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 22: Japan 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

CHINA
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2023 (E)
Table 23: China Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 24: China Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 25: China 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

EUROPE
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 26: Europe Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR

Table 27: Europe Historic Review for Oncology Based In-Vivo CRO
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 28: Europe 16-Year Perspective for Oncology Based In-Vivo
CRO by Geographic Region - Percentage Breakdown of Value Sales
for France, Germany, Italy, UK and Rest of Europe Markets for
Years 2014, 2023 & 2030

Table 29: Europe Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 30: Europe Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 31: Europe 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

FRANCE
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2023 (E)
Table 32: France Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 33: France Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 34: France 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

GERMANY
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 35: Germany Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 36: Germany Historic Review for Oncology Based In-Vivo
CRO by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 37: Germany 16-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2014, 2023 & 2030

ITALY
Table 38: Italy Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 39: Italy Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR

Table 40: Italy 16-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2014, 2023 & 2030

UNITED KINGDOM
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2023
(E)
Table 41: UK Recent Past, Current & Future Analysis for
Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood
Cancer and Other Indications - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR

Table 42: UK Historic Review for Oncology Based In-Vivo CRO by
Indication - Solid Tumors, Blood Cancer and Other Indications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR

Table 43: UK 16-Year Perspective for Oncology Based In-Vivo CRO
by Indication - Percentage Breakdown of Value Sales for Solid
Tumors, Blood Cancer and Other Indications for the Years 2014,
2023 & 2030

REST OF EUROPE
Table 44: Rest of Europe Recent Past, Current & Future Analysis
for Oncology Based In-Vivo CRO by Indication - Solid Tumors,
Blood Cancer and Other Indications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2022 through 2030
and % CAGR

Table 45: Rest of Europe Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Table 46: Rest of Europe 16-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2014, 2023 & 2030

ASIA-PACIFIC
Oncology Based In-Vivo CRO Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 47: Asia-Pacific Recent Past, Current & Future Analysis
for Oncology Based In-Vivo CRO by Indication - Solid Tumors,
Blood Cancer and Other Indications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2022 through 2030
and % CAGR

Table 48: Asia-Pacific Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Table 49: Asia-Pacific 16-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2014, 2023 & 2030

REST OF WORLD
Table 50: Rest of World Recent Past, Current & Future Analysis
for Oncology Based In-Vivo CRO by Indication - Solid Tumors,
Blood Cancer and Other Indications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2022 through 2030
and % CAGR

Table 51: Rest of World Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2021 and % CAGR

Table 52: Rest of World 16-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2014, 2023 & 2030

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06032380/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

 

            











    

        

        
Contact Data